Report Overview

There is strong potential for growth in the global pneumonia therapeutics market. The growing healthcare expenditure across developed nations, such as Germany, Japan, Brazil, and the United States demonstrates an increasing investment in clinical research and development, which is driving the growth of the global pneumonia therapeutics market.

Global Pneumonia Therapeutics Market - Industry Trends & Forecast Report 2027

The global pneumonia therapeutics market is showing significant growth in recent years and reached a market valuation of USD 14,804.2 million in 2021. The market is further anticipated to reach USD 25,659.6 million in 2028 with a significant CAGR of 8.3% during the forecast period, i.e., 2022-2028. The increasing healthcare expenditure in developed nations, such as Germany, Japan, Brazil, and the United States indicates an increased investment in clinical research and development, allowing more drug therapeutics to be developed to treat pneumonia. In April 2020, GPN Vaccines announced that the South Australian Government's Research, Commercialization, and Startup Fund (RCSF) awarded more than USD 720,000 to support the first clinical trial on the company's broad-spectrum pneumonia vaccine. Moreover, the growing vulnerabilities caused by viruses like COVID-19 are encouraging companies to invest more in R&D to develop pneumococcal vaccines, which consequently are helping to drive the market's growth.

Pneumonia Therapeutics Overview

Pneumonia happens to be an infection inflaming the air sacs of one or both lungs of a living body. The air sacs may get filled with pus or fluid (purulent like material), initiating cough along with phlegm, fever, difficulty breathing coupled with chills. A wide variety of organisms, including bacteria, fungi, and viruses, can cause pneumonia. Various methods of diagnosis and treatment are used in the therapeutics of the disease. If bacteria cause pneumonia, the patient will be treated using an antibiotic. Typical antibiotics have not been found to work properly against viruses. In case a patient has viral pneumonia, the doctor may prescribe an antiviral medication for treating it. Sometimes, symptom management and proper rest are also required for the recovery of a patient.

Pneumonia Therapeutics Market Trends

Growth Drivers

Growing Geriatric Population With Weaker Immune Systems Driving Market Growth

As per the U.S. National Library of Medicine, the geriatric population or people who are aged more than 60 years or more are the most susceptible to pneumonia. The prognosis (duration of the condition) exacerbates with age, meaning it requires more time for the elderly to recover from it. Furthermore, elderly patients who catch pneumonia have a mortality rate of 20%. According to the Statistics Bureau of Japan, the population falling into the 65 years old and over age group across Japan stood at approximately 36.19 million, accounting for 28.8% of the total population in 2020. The same statistic was found at around 26.6% in 2015, indicating a rapid increase in the aged population across Japan. Not only that, Italy, Portugal, Finland, and Greece follow Japan in terms of the old age population, where 23.30%, 22.77%, 22.55%, 22.28% (respectively) of the population is geriatric and have been recording an upward trend, according to the World Bank. Rising geriatric populations add stress to the healthcare system, thus creating a higher demand for therapeutics to fight pneumonia's immune response at home and prevent the healthcare system from collapsing. This is a major factor contributing to the growth of the global pneumonia therapeutics market.

Restraints

Shortage Of Pulmonologists Across Developed Regions Impeding Market Growth

In addition to the shortage of lung specialists, the global market for pneumonia therapeutics is impacted by the shortage of pulmonologists. An estimated 37,700 to 123,000 physicians will be short-staffed in the United States by the end of 2034, according to a report released by the Association of American Medical Colleges in June 2021. In the same estimate, the organization stated that pulmonology specialists fall under the Medical specialties segment (including cardiology, infectious diseases, oncology, pulmonology professionals), which are projected to decrease by 3,800 to 13,400 by 2034. With such a narrowing professional pool, along with the already declining fertility rate and growing life expectancy in the United States, a lot of challenges are expected, including improper or no treatment of pneumonia-associated diseases, and misdiagnosis of the disease, among others.

Impact of COVID-19 on the Global Pneumonia Therapeutics Market

The COVID-19 pandemic severely impacted every industry worldwide as the government authorities decided on undertaking strict measures to eradicate or curb the spread of the virus. The healthcare calamity led to the shutdown of various industries, including the pharmaceutical companies. The pharmaceutical industry, however, started seeing some discretion after the initial lockdown phase, which kept the societal structure from imploding.

Nevertheless, it caused disruptions in the supply of raw materials and active pharmaceutical ingredients, resulting in stagnant growth of the products. Although some medicinal products, such as Remdesevir and Baricitinib, showed some positive signs for COVID-19 patients, the production couldn't satisfy the demand generated due to black marketing and hoarding carried out in some developing nations around the world.

On the other hand, the demand side of the market had skyrocketed due to the growing number of pneumonia cases experienced by the patients due to the COVID-19. In some countries, 8 out of 10 people were exposed to COVID-19 pneumonia, adding to the severity of the disease and contributing to the death toll across the globe.

Global Pneumonia Therapeutics Market- By Therapeutics

Based on therapeutics, the global pneumonia therapeutics market can be bifurcated into prevention vaccines, treatment drugs, and oxygen therapy. The prevention vaccines segment accounted for the largest share in the global pneumonia therapeutics market. In contrast to this, the oxygen therapy segment of the market is projected to record the fastest CAGR during the forecast period, 2022-2028. Growing demand for in-house treatment and rising demand for medical-grade oxygen is expected to support the growth of the oxygen therapy segment in the global pneumonia therapeutics market

Global Pneumonia Therapeutics Market- By Drug Class

Based on drug class, the global pneumonia therapeutics market is segmented into Antibacterial Drugs (Macrolide, Quinolones, and Others), Antiviral Drugs, and Antifungal Drugs. The antibacterial drugs segment dominated drug class segment in the global pneumonia therapeutics market in 2021. Bacterial pneumonia poses a much higher threat to the heart than viral pneumonia, and this factor is expected to support the growth of antibacterial drugs segment in the global pneumonia therapeutics market during the forecast period.

On the other hand, antiviral drugs are expected to register the highest CAGR during the forecast period owing to viral pneumonia spreading through a fluid found in the air dew after a distinct cough or sneeze. Various remedial options (including Oseltamivir and Acyclovir) are available to diminish the severity of flu viruses in the body. These options are expected to induce the segment’s growth during the forecast period.

Global Pneumonia Therapeutics Market- By Infection Type

Based on infection types, the global pneumonia therapeutics market is segmented into Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], and Ventilator-associated Pneumonia [VAP]. Among these segments, the HAP-acquired Pneumonia segment acquired the largest share in 2021, as hospital-acquired pneumonia is a lung contamination that occurs during hospital stays, which leads to serious issues such as renal failure, respiratory failure, and empyema. Increasing incidences of hospital-acquired pneumonia will induce the demand for pneumonia therapeutics drugs during the forecast period.

Global Pneumonia Therapeutics Market- Regional Insights

Based on regions, the Pneumonia Therapeutics market is categorized into North America, Europe, the Asia-Pacific, Latin America, and the Middle East & Africa. The markets in North America and Europe hold vital market share because of the well-developed healthcare sector, increasing occurrences of community-acquired pneumonia, and the presence of well-known players operating in the target market through various countries in this region. However, the market in the Asia Pacific is anticipated to see the fastest growth, owing to growing government spending on healthcare sector and the presence of leading players in developing economies, such as India and China.

 

Competitive Landscape

The major players in the global pneumonia therapeutics market are Sanofi S.A., Eli Lilly & Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Baxter International Inc., Bayer AG, Lupin Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Abbott Laboratories, AstraZeneca plc, and other prominent players.

The global pneumonia therapeutics market is moderately consolidated. Due to this consolidation, the well-established players in the market possess a higher influence at altering the prices of their products, rendering it difficult for consumers to opt for a cheaper alternative. With the increasing number of vaccine trials conducted by major competitors and the rising supply chain problems, the already established players will be able to augment their market shares, leading to more consolidation in the coming years. Consequently, it is expected that the chances of newer entrants or emerging players in the market will diminish in the foreseeable future.

 

Recent Developments

 

• November 2021: GlaxoSmithKline plc and Vir Biotechnology, Inc. announced U.S. government contracts worth approximately USD 1 billion (USD) for the purchase of Sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, for which the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) in May 2021.

 

• October 2021: As part of its long-term plan, GSK has announced plans for major new headquarters in the UK and global campus for the Consumer Healthcare company following separation in 2022.

 

• June 2021: Pfizer Inc. announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for its PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine). PREVNAR provides prevention from invasive disease and pneumonia breeding from 20 Streptococcus pneumoniae serotypes present in the vaccine across adults aged 18 years and more. After receiving the FDA approval, the U.S. Centers for Disease Control and Prevention (CDC)'s and ACIP (Advisory Committee on Immunization Practices) is also anticipated to discuss and update their recommendations on pneumococcal vaccines' safe and appropriate consumption.

 

Scope of Report

Attribute	Details
Years Considered	Historical data – 2018-2021
	Base Year – 2021
	Forecast – 2022 – 2028
Facts Covered	Revenue in USD Million
Market Coverage	United States, Germany, United Kingdom, France, Canada, Italy, Spain, China, Japan, South Korea, Brazil, Mexico, India, Argentina, , United Arab Emirates, South Africa, Saudi Arabia.
Product/Service Segmentation	By Therapeutics, By Drug Class, By Age Group, By Infection Type, By Distribution Channel, By Region
Key Players	Key players in the market are Eli Lilly & Company, Sanofi S.A.,  Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Baxter International Inc., Bayer AG, Lupin Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Abbott Laboratories, AstraZeneca plc, and other prominent players.

 

By Therapeutics

• Prevention Vaccine
• Treatment Drugs
• Oxygen Therapy

By Drug Class

• Antibacterial Drugs
  • Macrolide
  • Quinolones
  • Others
• Antiviral Drugs
• Antifungal Drugs

By Age Group

• Paediatric
• Adult
• Geriatric

By Infection Type

• Hospital-acquired Pneumonia [HAP]
• Community-acquired Pneumonia [CAP]
• Ventilator-associated Pneumonia [VAP]

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Europe
• The Asia-Pacific
• Latin America
• The Middle-East & Africa

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Research Methodology
   1. Qualitative Research
      1. Primary & Secondary Research
   2. Quantitative Research
   3. Market Breakdown & Data Triangulation
      1. Primary & Secondary Research End-use Vendors  
      2. Secondary Research
      3. Primary Research
   4. Breakdown of Primary Research Respondents, By Region
   5. Assumption & Limitation
3. Executive Summary
4. Global Pneumonia Therapeutics Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   3. Porter’s Five Forces Analysis
      1. Bargaining End-use Industry of Suppliers
      2. Bargaining End-use Industry of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
   4. Recent Development/ Technological Advancement
   5. Regulatory Insights
5. Global Pneumonia Therapeutics Market Overview
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutics
         1. Prevention Vaccine
         2. Treatment Drugs
         3. Oxygen Therapy
      2. By Drug Class
         1. Antibacterial Drugs
            1. Macrolide
            2. Quinolones
            3. Others
         2. Antiviral Drugs
         3. Antifungal Drugs
      3. By Age Group
         1. Paediatric
         2. Adult
         3. Geriatric
      4. By Infection Type
         1. Hospital-acquired Pneumonia [HAP]
         2. Community-acquired Pneumonia [CAP]
         3. Ventilator-associated Pneumonia [VAP]
      5. By Distribution Channel
         1. Hospital Pharmacies
         2. Retail Pharmacies
         3. Online Pharmacies
      6. By Region

               5.2.3.1. North America

5.2.3.2. Europe

               5.2.3.3. Asia-Pacific

5.2.3.4. Latin America

               5.2.3.5. Middle East and Africa

6. North Pneumonia Therapeutics Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutics
      2. By Drug Class
      3. By Age Group
      4. By Infection Type
      5. By Distribution Channel
      6. By Country
         1. U.S.
         2. Canada
7. Europe Pneumonia Therapeutics Market 
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutics
      2. By Drug Class
      3. By Age Group
      4. By Infection Type
      5. By Distribution Channel
      6. By Country
         1. France
         2. Germany
         3. Italy
         4. Spain
         5. Rest of Europe
8. The Asia-Pacific (APAC) Pneumonia Therapeutics Market 
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutics
      2. By Drug Class
      3. By Age Group
      4. By Infection Type
      5. By Distribution Channel
      6. By Country
         1. Japan
         2. China
         3. India
         4. South Korea
         5. Rest of APAC
9. Latin America Pneumonia Therapeutics Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapeutics
      2. By Drug Class
      3. By Age Group
      4. By Infection Type
      5. By Distribution Channel
      6. By Country
         1. Brazil
         2. Argentina
         3. Mexico
         4. Rest of Latin America
10. The Middle East & Africa (MEA) Pneumonia Therapeutics Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Therapeutics
       2. By Drug Class
       3. By Age Group
       4. By Infection Type
       5. By Distribution Channel
       6. By Country
          1. South Africa
          2. Saudi Arabia
          3. U.A.E.
          4. Rest of MEA
11. Competitive Landscape
    1. List of Key Players and their Offerings
    2. Company Market Share Analysis, 2021
    3. Competitive Benchmarking, By Operating Parameters
12. Impact of Covid-19 across Global Pneumonia Therapeutics Market
13. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

 

13. 1. Merck & Co, Inc
    2. Sanofi SA
    3. AstraZeneca plc
    4. Eli Lilly and Company
    5. Teva Pharmaceutical Industries Ltd
    6. Abbvie Inc
    7. Novartis International AG
    8. Abbott Laboratories
    9. Bayer AG
    10. Pfizer Inc
    11. GlaxoSmithKline Plc
    12. Lupin Pharmaceuticals, Inc
14. Key Strategic Recommendations

 

*Financial details of unlisted companies will be available as per data availability in the final deliverable

**The segmentation and the companies are subjected to modifications based on the in-depth secondary for the final deliverable

 

List of figures

Fig 1: Global Pneumonia Therapeutics Market Segmentation

Fig 2: Global Pneumonia Therapeutics Market Size, By Value (USD Million)

Fig 3: Global Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value (in %), 2021

Fig 4: Global Pneumonia Therapeutics Market Industry Value Chain Analysis

Fig 5: Global Pneumonia Therapeutics Market Industry Players

Fig 6: Global Pneumonia Therapeutics Market Share: Market Share Analysis, 2021

Fig 7: Porters Five Forces Analysis

Fig 8: Global Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028

Fig 9: Global Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028

Fig 10: Global Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028

Fig 11: Global Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Fig 12: Global Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028

Fig 13: Global Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028

Fig 14: Global Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028

Fig 15: Global Pneumonia Therapeutics Market Share (%), By Region, By Value, 2018-2028

Fig 16: North America Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028

Fig 17: North America Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028

Fig 18:  North America Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028

Fig 19:  North America Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Fig 20:  North America Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028

Fig 21:  North America Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028

Fig 22:  North America Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028

Fig 23:  North America Pneumonia Therapeutics Market Share (%), By Country, By Value, 2018-2028

Fig 24: Europe Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028

Fig 25: Europe Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028

Fig 26:  Europe Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028

Fig 27:  Europe Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Fig 28:  Europe Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028

Fig 29:  Europe Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028

Fig 30:  Europe Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028

Fig 31:  Europe Pneumonia Therapeutics Market Share (%), By Country, By Value, 2018-2028

Fig 32: Asia-Pacific Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028

Fig 33: Asia-Pacific Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028

Fig 34:  Asia-Pacific Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028

Fig 35:  Asia-Pacific Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Fig 36:  Asia-Pacific Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028

Fig 37:  Asia-Pacific Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028

Fig 38:  Asia-Pacific Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028

Fig 39:  Asia-Pacific Pneumonia Therapeutics Market Share (%), By Country, By Value, 2018-2028

Fig 40: Latin America Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028

Fig 41: Latin America Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028

Fig 42:  Latin America Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028

Fig 43:  Latin America Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Fig 44:  Latin America Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028

Fig 45:  Latin America Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028

Fig 46:  Latin America Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028

Fig 47:  Latin America Pneumonia Therapeutics Market Share (%), By Country, By Value, 2018-2028

Fig 48: Middle East & Africa Pneumonia Therapeutics Market Size, By Value (USD Million), 2018-2028

Fig 49: Middle East & Africa Pneumonia Therapeutics Market Share (%), By Therapeutics, By Value, 2018-2028

Fig 50:  Middle East & Africa Pneumonia Therapeutics Market Share (%), By Drug class, By Value, 2018-2028

Fig 51:  Middle East & Africa Pneumonia Therapeutics Market Share (%), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Fig 52:  Middle East & Africa Pneumonia Therapeutics Market Share (%), By Age Group, By Value, 2018-2028

Fig 53:  Middle East & Africa Pneumonia Therapeutics Market Share (%), By Infection Type, By Value, 2018-2028

Fig 54:  Middle East & Africa Pneumonia Therapeutics Market Share (%), By Distribution Channel, By Value, 2018-2028

Fig 55:  Middle East & Africa Pneumonia Therapeutics Market Share (%), By Country, By Value, 2018-2028

 

List of Tables

 

Table 1: Global Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028

Table 2: Global Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028

Table 3: Global Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Table 4: Global Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028

Table 5: Global Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028

Table 6: Global Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028

Table 7: Global Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028

Table 8:  North America Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028

Table 9:   North America Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028

Table 10:   North America Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Table 11:   North America Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028

Table 12:   North America Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028

Table 13:   North America Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028

Table 14:   North America Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028

Table 15:  Europe Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028

Table 16:   Europe Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028

Table 17:   Europe Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Table 18:   Europe Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028

Table 19:   Europe Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028

Table 20:   Europe Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028

Table 21:   Europe Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028

Table 22:  Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028

Table 23:   Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028

Table 24:   Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Table 25:   Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028

Table 26:   Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028

Table 27:   Asia-Pacific Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028

Table 28:   Asia-Pacific Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028

Table 29:  Latin America Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028

Table 30:   Latin America Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028

Table 31:   Latin America Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Table 32:   Latin America Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028

Table 33:   Latin America Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028

Table 34:   Latin America Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028

Table 35:   Latin America Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028

Table 36:  Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Therapeutics, By Value, 2018-2028

Table 37:   Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Drug Class, By Value, 2018-2028

Table 38:   Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Drug Class, For Antibacterial Drugs, By Value, 2018-2028

Table 39:   Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Age Group, By Value, 2018-2028

Table 40:   Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Infection Type, By Value, 2018-2028

Table 41:   Middle East & Africa Pneumonia Therapeutics Market Size (USD Million), By Distribution Channel, By Value, 2018-2028

Table 42:   Middle East & Africa Pneumonia Therapeutics Market Size. By Region, By Value (USD Million), 2018-2028

Table 43:  Merck & Co., Inc. Company Overview

Table 44:  Merck & Co. Financial Analysis (USD Million)

Table 45:  Sanofi S.A. Company Overview

Table 46:  Sanofi S.A Financial Analysis (USD Million)

Table 47:  AstraZeneca plc Company Overview

Table 48:  AstraZeneca plc Financial Analysis (USD Million)

Table 49:  Eli Lilly and Company Overview

Table 50:  Eli Lilly and Company Financial Analysis (USD Million)

Table 51:  Teva Pharmaceutical Industries Ltd. Company Overview

Table 52:  Teva Pharmaceutical Financial Analysis (USD Million)

Table 53:  Abbvie Inc. Company Overview

Table 54:  Abbvie Inc. Financial Analysis (USD Million)

Table 55:  Novartis International AG Company Overview

Table 56:  Novartis International AG Financial Analysis (USD Million)

Table 57:  Abbott Laboratories Company Overview

Table 58:  Abbott Laboratories Financial Analysis (USD Million)

Table 59:  Bayer AG Company Overview

Table 60:  Bayer AG Financial Analysis (USD Million)

Table 61:  Pfizer Inc. Company Overview

Table 62:  Pfizer Inc. Financial Analysis (USD Million)

Table 63:  GlaxoSmithKline Plc. Limited Company Overview

Table 64:  GlaxoSmithKline Plc. Financial Analysis (USD Million)

Table 65:  Lupin Pharmaceuticals, Inc., Company Overview

Table 66:  Lupin Pharmaceuticals, Inc., Financial Analysis (USD Million)